Plain-English translation of NCT05888870 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether combining (a clotting factor replacement) with daratumumab (a medication that helps calm an overactive immune response) works better than alone for people with hemophilia A who have developed inhibitors. Inhibitors are antibodies the body makes that block clotting factor therapy from working. The study aims to help the immune system accept and tolerate the clotting factor treatment so it works properly again.
When people with hemophilia A receive clotting factor therapy repeatedly, their immune system sometimes fights back by creating inhibitors that block the treatment from working. This medication combination is being tested to see if adding an immune-modifying drug helps reset the immune system faster and more effectively than the clotting factor alone.
You likely qualify if…
You likely don't qualify if…
You will receive either clotting factor injections three times per week combined with daratumumab infusions, or injections alone. After 3 months, your doctor may add other immune-supporting medications if needed. You will have regular visits to monitor how well your immune system is tolerating the treatment and how effective it is at restoring clotting factor function.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China